Global Mycoplasma Detection System Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Research Team, the global Mycoplasma Detection System Market is expected to record a CAGR of 12% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 0.8 Billion. By 2032, the valuation is anticipated to reach USD 2.3 Billion.

Mycoplasma testing involves the process of identifying and detecting mycoplasma bacteria present in biological samples, including but not limited to cell cultures and clinical specimens. Mycoplasma, a group of diminutive bacteria characterized by the absence of a cell wall, exhibits resilience in diverse environments, including laboratory cell cultures.

Their propensity to contaminate these cultures can result in cell behavior and characteristic alterations, subsequently impacting the accuracy and reliability of research outcomes. Thus, mycoplasma testing assumes a critical role in cell culture research and the production of biological products, serving as a vital safeguard to ensure the integrity and purity of these cultures while effectively mitigating the risk of contamination.

Mycoplasma Detection System Market - Significant Growth Factors

The mycoplasma testing market is witnessing growth and innovation within the diagnostic industry. This growth is primarily driven by the escalating incidences of mycoplasma contaminations in the pharmaceutical and biotechnology sectors, presenting a significant opportunity for the expansion of the mycoplasma testing market.

A key contributing factor to this market growth is the surging demand for mycoplasma testing products, particularly from the biopharmaceutical industry. The biopharmaceutical sector is experiencing rapid expansion, and the production of biopharmaceuticals necessitates stringent quality control measures, among which mycoplasma testing holds paramount importance.

Consequently, there is a heightened demand for mycoplasma testing products and services, fueled by increased research activities within the biotechnology and biopharmaceutical domains. This trend underscores the pivotal role of mycoplasma testing in ensuring product purity and quality control within these industries.

The mycoplasma testing market is experiencing growth, thanks to notable technological advancements that have led to the development of faster and more precise mycoplasma testing methods and instruments. These innovations are contributing to the expansion of the market's share.

For instance, Minerva Biolabs GmbH offers the VenorGeM Advance Kit, a highly sensitive and specific solution designed for the detection of mycoplasma contamination in various biological matrices, including cell cultures. Similarly, Sartorius AG provides the Microsart Mycoplasma qPCR Detection Assay Kits, which are rapid and compliant with industry guidelines for mycoplasma detection. These kits are recognized for their exceptional specificity and sensitivity, delivering rapid results that are invaluable in pharmaceutical quality control processes.

Furthermore, the growing demand for biologics and biosimilars is a significant driver of market expansion. Mycoplasma contamination poses a potential threat during the manufacturing of biologics and biosimilars, compromising product quality, efficacy, and patient safety. As the demand for biologics and biosimilars continues to surge, the necessity for effective mycoplasma testing solutions is on the rise, further bolstering market growth.

For example, as of April 2021, the Food and Drug Administration (FDA) has greenlit 29 biosimilars, with 20 of them already launched in the U.S. Moreover, an uptick in promotional efforts by manufacturers and heightened awareness regarding mycoplasma testing are anticipated to stimulate adoption in the near future.

Conversely, the mycoplasma testing market faces challenges stemming from the elevated expenses associated with mycoplasma testing kits and instruments, as well as the scarcity of proficient laboratory technicians. These factors collectively impede the adoption of mycoplasma testing products and exert a dampening effect on market expansion.

For instance, consider SouthernBiotech's Mycoplasma Detection Kit, which commands a price range of approximately $200 to $250. Moreover, when it comes to mycoplasma testing for patient specimens such as tissue, blood, and other bodily secretions, the costs can reach around $210. Consequently, the substantial costs associated with mycoplasma testing products, attributable to their specialized kits and reagents, are poised to hinder market growth.

Mycoplasma Detection System Market - Mergers and Acquisitions

• Thermo Fisher Scientific Acquires Becton, Dickinson and Company (BD): In March 2017, Thermo Fisher Scientific, a leading life sciences company, acquired the assets of BD's Advanced Bioprocessing business. This strategic move bolstered Thermo Fisher's capabilities in the field of bioproduction, including mycoplasma detection technologies.

• Lonza Group Acquires Vivante GMP Solutions: In October 2020, Lonza Group, a global leader in life sciences, completed the acquisition of Vivante GMP Solutions, a provider of mycoplasma testing services and technology. This acquisition strengthened Lonza's offerings in the field of cell and gene therapy manufacturing.

• PromoCell Acquires CellSystems Biotechnologie AG: In November 2018, PromoCell, a leading manufacturer of cell culture products, acquired CellSystems Biotechnologie AG. This acquisition expanded PromoCell's portfolio of mycoplasma detection and elimination products, supporting cell culture quality control.

• Merck KGaA Acquires Sigma-Aldrich: In 2015, Merck KGaA acquired Sigma-Aldrich, a major provider of life science and technology products. This acquisition expanded Merck's portfolio of research tools, including mycoplasma detection and prevention products.

• Eurofins Scientific Acquires QTA Testing: In August 2021, Eurofins Scientific, a global leader in laboratory testing services, acquired QTA Testing, a provider of mycoplasma testing and biopharmaceutical services. This acquisition enhanced Eurofins' capabilities in biopharmaceutical testing.

• Minerva Biolabs Acquires R-Biopharm: In June 2021, Minerva Biolabs, a provider of mycoplasma testing solutions, acquired R-Biopharm AG's Cell Culture Diagnostics business. This acquisition expanded Minerva Biolabs' product portfolio for cell culture quality control.

• SGS Acquires M-Scan: In 2019, SGS, a global leader in inspection, verification, testing, and certification services, acquired M-Scan, a contract research organization specializing in mycoplasma testing services for the biopharmaceutical industry. This acquisition strengthened SGS's offerings in biopharmaceutical testing.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Mycoplasma Detection System Market - Significant Threats

• High Cost of Testing: The cost associated with mycoplasma detection tests, especially when conducted on a large scale, can be substantial. This expense may discourage some research laboratories and biopharmaceutical companies from conducting routine mycoplasma testing.

• Technical Expertise: Effective mycoplasma testing requires technical expertise and specialized equipment. The shortage of skilled laboratory technicians with expertise in mycoplasma detection methods can hinder the adoption of these tests.

• Sample Contamination: Cross-contamination between samples during mycoplasma testing can lead to false-positive results. Ensuring proper laboratory protocols and hygiene is essential to mitigate this risk.

• False-Negative Results: Mycoplasma bacteria are not always present in uniform concentrations in biological samples. As a result, some mycoplasma tests may yield false-negative results, leading to undetected contamination.

• Rapid Mutation: Mycoplasma bacteria have a propensity for rapid mutation, which can result in changes in their genetic makeup and antigenic properties. This genetic diversity can make it challenging to detect all mycoplasma strains using standard tests.

• Market Fragmentation: The mycoplasma detection market is characterized by a multitude of testing methods and technologies. This fragmentation can make it challenging for end-users to select the most suitable and reliable testing approach.

• Regulatory Compliance: Meeting regulatory requirements for mycoplasma testing, especially in the biopharmaceutical industry, can be demanding. Companies must ensure their testing methods and equipment comply with industry-specific regulations.

• Emerging Technologies: The continuous development of new and advanced technologies for mycoplasma detection requires companies to stay updated and adapt to evolving market trends and customer preferences.

• Global Health Events: Unforeseen global health events, such as pandemics or natural disasters, can disrupt supply chains, impact laboratory operations, and affect the availability of mycoplasma testing products.

• Data Privacy and Security: As mycoplasma testing becomes increasingly digitized and connected, concerns about data privacy and security may arise. Ensuring the confidentiality and integrity of sensitive testing data is critical.

• Market Competition: Intense competition among companies offering mycoplasma testing products and services can lead to price wars and decreased profit margins.

Report Scope

Category-Wise Insights

By Product Type:

In 2022, the segment dedicated to kits and reagents emerged as the top revenue generator, commanding a significant share of 51.63% within the mycoplasma detection market. This dominance can be attributed to the robust demand for these products in mycoplasma detection procedures, coupled with their relatively higher cost.

Market players have proactively developed specialized mycoplasma detection kits tailored to the specific requirements of researchers and biopharmaceutical manufacturers. This strategic focus on creating tailored solutions has driven substantial growth within this segment.

Furthermore, the mycoplasma detection landscape is witnessing an increasing availability of automated equipment designed for efficient mycoplasma detection. Consequently, the instruments segment is poised to experience noteworthy growth throughout the projected period.

To learn more about this report - request a sample report PDF

By Technology:

The PCR (Polymerase Chain Reaction) segment asserted its dominance in the mycoplasma testing market, capturing a substantial revenue share of 33.38% in 2022. Moreover, it stands out as the fastest-growing segment throughout the projected period.

PCR is an approach that allows for the isolation of other contaminating DNA elements while simultaneously facilitating the detection of a wide range of mycoplasma species. This method offers highly efficient and specific test results, rendering it particularly advantageous. One of the key benefits offered by PCR technology is its user-friendliness and rapid detection capabilities.

For instance, Merck KGaA has introduced the LookOut Mycoplasma PCR Detection Kit, simplifying the process of identifying contamination with Ureaplasma, Mycoplasma, and Acholeplasma in cell-derived biologicals and cell culture lines. This exemplifies the convenience and efficiency that PCR-based methods bring to mycoplasma detection.

Mycoplasma Detection Market - Regional Analysis

• North America: North America, particularly the United States and Canada, boasts a significant share in the mycoplasma detection market. This prominence is attributed to a robust biotechnology and pharmaceutical industry, extensive research and development activities, and stringent regulatory standards. Additionally, the region's focus on biopharmaceutical production fuels the demand for mycoplasma testing to ensure product quality and safety.

• Europe: Europe is another prominent player in the mycoplasma detection market, with countries such as Germany, the United Kingdom, and France leading the way. The region benefits from a well-established healthcare infrastructure and a thriving biopharmaceutical sector. The stringent regulations regarding the safety and quality of biologics contribute to the adoption of mycoplasma testing solutions.

• Asia-Pacific: The Asia-Pacific region, including countries like China, Japan, and India, is witnessing substantial growth in mycoplasma detection. The increasing presence of biopharmaceutical companies, research organizations, and contract manufacturing facilities drives demand. Additionally, government initiatives to support biotechnology research and development further bolster market growth.

• Latin America: Latin America is emerging as a promising market for mycoplasma detection, mainly due to the growth of the biopharmaceutical industry and rising research activities. Brazil and Mexico are key contributors to the regional market.

List of the prominent players in the Mycoplasma Detection System Market:

• InvivoGen
• Lonza
• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• Bionique Testing Laboratories LLC
• ATCC
• Norgen Biotek Corp.
• Bio-Rad Laboratories Inc
• Hoffmann-La Roche Ltd.
• Charles River Laboratories
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America